ConductScience.org, home

Paper39264187

An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.

Duffy S and 2 others. Antimicrob Agents Chemother, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds. Papers, record 39264187. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39264187

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.94, provisional
iCite
Revised in PubMed
2025-08-25
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Duffy SSandrahttps://orcid.org/0000-0002-2814-1193
2Sleebs BEBrad Ehttps://orcid.org/0000-0001-9117-1048
3Avery VMVicky Mhttps://orcid.org/0000-0003-4914-2299

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AntimalarialsMajor topic
High-Throughput Screening AssaysMajor topic
Plasmodium falciparum
Humans
Drug Discovery
Malaria
Animals
Parasitic Sensitivity Tests

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
AP1150359DHAC | National Health and Medical Research Council (NHMRC)PubMed

Source PubMed

Download CSV of grants

References64

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1394674Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.Antimicrob Agents Chemother1979https://conductscience.org/library/papers/394674PubMed
238486232A phenotypic screen of the Global Health Priority Box identifies an insecticide with anthelmintic activity.Parasit Vectors2024https://conductscience.org/library/papers/38486232PubMed
318579134Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter.Exp Parasitol2008https://conductscience.org/library/papers/18579134PubMed
425007124N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.J Med Chem2014https://conductscience.org/library/papers/25007124PubMed
535647647High-Throughput Screening Platform To Identify Inhibitors of Protein Synthesis with Potential for the Treatment of Malaria.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35647647PubMed
624731288Repositioning: the fast track to new anti-malarial medicines?Malar J2014https://conductscience.org/library/papers/24731288PubMed
722877082Review of pyronaridine anti-malarial properties and product characteristics.Malar J2012https://conductscience.org/library/papers/22877082PubMed
835229610Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria.J Med Chem2022https://conductscience.org/library/papers/35229610PubMed
937471441A screen of drug-like molecules identifies chemically diverse electron transport chain inhibitors in apicomplexan parasites.PLoS Pathog2023https://conductscience.org/library/papers/37471441PubMed
10223905383,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.J Med Chem2012https://conductscience.org/library/papers/22390538PubMed
1129311064High-Content Screening of the Medicines for Malaria Venture Pathogen Box for Plasmodium falciparum Digestive Vacuole-Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29311064PubMed
1231665424The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest.J Antimicrob Chemother2020https://conductscience.org/library/papers/31665424PubMed
1325453091(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/25453091PubMed
1429355852Drug resistance in Plasmodium.Nat Rev Microbiol2018https://conductscience.org/library/papers/29355852PubMed
1529892073Diverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasis.Sci Rep2018https://conductscience.org/library/papers/29892073PubMed
1628446690Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.Sci Transl Med2017https://conductscience.org/library/papers/28446690PubMed
1734452759Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.Bioorg Chem2021https://conductscience.org/library/papers/34452759PubMed
1822383983P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action.PLoS One2012https://conductscience.org/library/papers/22383983PubMed
1933929818Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors.ACS Infect Dis2021https://conductscience.org/library/papers/33929818PubMed
2037435490Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37435490PubMed

See all 64 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42662730Drug Repositioning for Multiresistant Staphylococcus aureus and Escherichia coli from Pandemic Response Box and Global Health Priority Box of MMV.ACS Omega2026https://conductscience.org/library/papers/42662730PubMed
42085784Unpacking boxes: identification of novel inhibitors of malaria parasite invasion.Int J Parasitol Drugs Drug Resist2026https://conductscience.org/library/papers/42085784PubMed
41970896Indole Peptidomimetics Show Potent and Selective Activity against Drug-Resistant Plasmodium falciparum.ACS Omega2026https://conductscience.org/library/papers/41970896PubMed
41009722Targeting Mitochondrial Function in Plasmodium falciparum: Insight into Antimalarial Drugs and the Emerging Role of Saccharomyces cerevisiae as a Model System.Int J Mol Sci2025https://conductscience.org/library/papers/41009722PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39264187

GET https://conductscience.org/api/papers/v1/39264187/references?page=2